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Significance of this study
What is already known about this subject?
 ► Poor maternal glycemic control and excessive ges-
tational weight gain contribute to fetal overgrowth 
that is prevalent in pregnant women with type 2 
diabetes.
 ► Motivational interviewing is effective in promot-
ing adherence to diet programs and reducing 
body weight in non- pregnant patients with type 2 
diabetes.
What are the new findings?
 ► Motivational interviewing to improve adherence to 
healthy eating in pregnant women with type 2 diabe-
tes tended to reduce fetal overgrowth without major 
effect on gestational weight gain.
How might these results change the focus of 
research or clinical practice?
 ► Focus on motivation in clinical practice may improve 
pregnancy outcome in pregnant women with type 2 
diabetes.
 ► Further studies investigating the cost- benefit of en-
hancing motivation in pregnant women with diabe-
tes are needed.
AbStrAct
Objective To study how lifestyle coaching with 
motivational interviewing to improve adherence to healthy 
eating affects gestational weight gain and fetal growth 
in pregnant women with type 2 diabetes in a real- world 
setting.
Research design and methods A cohort study including 
a prospective intervention cohort of consecutive, singleton 
pregnant, Danish- speaking women with type 2 diabetes 
included between August 2015 and February 2018 and 
a historical reference cohort included between February 
2013 and August 2015. The intervention consisted of a 
motivational interviewing to improve adherence to healthy 
eating in addition to routine care. The reference cohort 
received routine care only. The main outcomes were 
gestational weight gain and large for gestational age (LGA) 
infants.
Results Ninety- seven women were included in the 
intervention cohort and 92 in the reference cohort. Pre- 
pregnancy body mass index (32.8±6.9 kg/m2 vs 32.4±7.4 
kg/m2, p=0.70), gestational weight gain (9.2±5.8 kg 
vs 10.2±5.8 kg, p=0.25), HbA1c in early pregnancy 
(6.7%±1.1% vs 6.5%±1.3% (50±12 mmol/mol vs 48±14 
mmol/mol), p=0.32) and late pregnancy (5.9%±0.5% 
vs 6.0%±0.6% (41±6 mmol/mol vs 42±7 mmol/mol), 
p=0.34) were comparable in the two cohorts. LGA infants 
occurred in 20% vs 31%, p=0.07, respectively, and after 
adjustment for maternal characteristics 14% vs 27% 
delivered LGA infants (p=0.04). Birth weight z- score was 
0.24±1.36 vs 0.61±1.38, p=0.06.
Conclusions Motivational interviewing to improve 
adherence to healthy eating in addition to routine care in 
pregnant women with type 2 diabetes tended to reduce 
fetal overgrowth without major effect on gestational weight 
gain. Further studies investigating the cost- benefit of 
enhancing motivation are needed.
Trial registration number NCT02883127.
InTROduCTIOn
The prevalence of type 2 diabetes in preg-
nancy is increasing,1 mainly due to decreased 
age of onset of type 2 diabetes.2
Fetal overgrowth is a major complication 
in women with type 2 diabetes and the prev-
alence of large for gestational age (LGA) 
infants is 23%–35%.3–5 Fetal overgrowth is 
associated with both maternal and neonatal 
complications, for example, shoulder 
dystocia, cesarean section and neonatal hypo-
glycemia6 7 and long- term offspring risk of 
obesity and diabetes.8
Excessive gestational weight gain contrib-
utes to fetal overgrowth in healthy women9 10 
and in women with diabetes independent of 
glycemic control and pre- pregnancy body mass 
index (BMI).5 11 12 However, obtaining appro-
priate gestational weight gain is challenging, 
especially in obese women,13 leading to a high 
prevalence of excessive gestational weight 
gain in women with type 2 diabetes.5 13–15 Life-
style intervention including diet, exercise or 
both combined during pregnancy in healthy 
women reduces the risk of excessive gesta-
tional weight gain on average by 20%.16
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Motivational interviewing that focuses on enhancing 
the women’s own motivation for lifestyle changes17 is 
effective in promoting adherence to diet and exercise 
programs18 and reducing body weight in non- pregnant 
patients with type 2 diabetes.19 During pregnancy, the 
Vitamin D and Lifestyle Intervention for GDM Prevention 
(DALI) study used motivational interviewing as an inter-
vention in overweight and obese pregnant women.20 The 
intervention that included both diet and physical activity 
reduced gestational weight gain by 2.3 kg compared with 
the control group.
Lifestyle intervention studies enhancing motivation in 
pregnant women with type 2 diabetes are lacking.
The aim of the present study was to investigate how life-
style coaching with motivational interviewing to improve 
adherence to healthy eating affects gestational weight 
gain and fetal growth in pregnant women with type 2 
diabetes in a real- world setting.
ReseaRCH desIgn and meTHOds
 study design
A cohort study consisting of a prospective intervention 
cohort and a historical reference cohort in a real- world 
setting. The intervention consisted of a motivational 
interviewing to improve adherence to healthy eating 
in addition to routine care and was offered to all preg-
nant women with type 2 diabetes. The reference cohort 
received routine care only. The goals for glycemic 
control and gestational weight gain were the same in the 
two cohorts as was the routine obstetrical control and 
management. The focus of the motivational interviewing 
was to encourage the women to follow the recommended 
diabetes diet21 and to comply to local gestational weight 
gain recommendations.22 Gestational weight gain (kg) 
and LGA infants (birth weight >90th percentile) were the 
main outcomes.
 study population
All consecutive women with type 2 diabetes from a 
geographically well- defined region of approximately 
4 million inhabitants were invited to participate from 
August 2015 to February 2018. The inclusion criteria 
were: singleton pregnancy before 20 weeks in women 
aged ≥18 years. All women were followed at either 
Center for Pregnant Women with Diabetes, Rigshospi-
talet or Department of Obstetrics and Endocrinology, 
Odense University Hospital. The women were registered 
as having type 2 diabetes, if the diagnosis was present at 
referral. Women diagnosed with type 2 diabetes in early 
pregnancy with HbA1c ≥6.5% (48 mmol/mol) were also 
included (the intervention cohort: n=4 and the reference 
cohort: n=3). Exclusion criteria were very few: previous 
bariatric surgery (n=3) and for ethical reasons, insuffi-
cient Danish language skills (n=40).
The reference cohort consisted of all pregnant women 
with type 2 diabetes treated at the centers in the period 
February 2013 to August 2015 and matched the same 
inclusion and exclusion criteria as the intervention 
cohort. If a woman had more than one pregnancy in 
the study period, the pregnancy in which she underwent 
intervention was the pregnancy included (n=9). Data for 
the reference cohort were registered prospectively but 
collected retrospectively.
 The lifestyle intervention with motivational interviewing
All women received individual one- to- one sessions with a 
lifestyle coach at each pregnancy visit at the centers, pref-
erably every 2 weeks. The lifestyle coaching was based on 
principles of patient empowerment and cognitive behav-
ioral techniques, inspired by motivational interviewing.17 
An individual action plan for improving dietary behavior 
was made during the first session and evaluated and 
tailored in subsequent sessions. At each visit the following 
dietary objectives were presented for the patient, of which 
one was to be achieved or maintained until the next 
session: (1) watch portion size—focus on the amount of 
carbohydrates in each meal; (2) eat mainly carbohydrates 
of low glycemic index (for example, more vegetables or 
whole grain products); (3) reduce the intake of carbo-
hydrate of high glycemic index (for example, less or no 
takeaway food, less or no cakes, candy, snacks, chips, ice 
cream, sugary beverage). Furthermore, the women were 
motivated to watch daily weight changes.
The lifestyle coaches were midwives, who had received 
special training in the motivational interviewing with 
focus on lifestyle changes as a part of the DALI study.20 
During the DALI study, the midwives had regular assess-
ment of their skills in the use of the motivational inter-
viewing and had years of practical experience. The first 
session of the motivational interviewing lasted 45 min. To 
minimize the time consumption for the patients and the 
caregivers, the sessions of motivational interviewing were 
thereafter sought combined with routine diabetes care 
within the time frame of one appointment, if possible. 
Women living a long distance from the clinic could 
convert a minor part of the one- to- one contacts to tele-
phone calls with the lifestyle coaches.
Women in the intervention cohort were judged to be 
compliant to the intervention, if attending at least 80% 
of the visits.
 The routine diabetes care for both cohorts
At the first pregnancy visit, the women received a one- 
to- one consultation with a nurse, a registered dietitian 
and a diabetologist. Thereafter, the women were seen by 
a diabetes caregiver preferably every 2 weeks throughout 
pregnancy.
The women received information from a dietitian 
about the recommended diabetes diet21 and education 
in carbohydrate exchange including an introduction to 
a local smartphone application with pictures and infor-
mation on the carbohydrate amounts to aid learning. 
The goals were: (1) adequate nutrient intake to support 
a healthy pregnancy; (2) carbohydrates mainly deriving 
from low glycemic index sources; and (3) a total daily 
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energy intake of approximately 1673 kcal (7000 kJ) 
including 175 g carbohydrates in total (43 E%) with 
approximately 150 g deriving from the major carbohy-
drate sources (bread, potatoes, rice, pasta, fruits, and 
dairy products).
The women were encouraged to be physically 
active for at least 30 min/day if this was not medically 
contraindicated.
The goals for gestational weight gain followed the 
Copenhagen guidelines22 for pregnant women with 
diabetes according to pre- pregnancy BMI, that is, pre- 
pregnancy BMI<25 kg/m2: aiming for 100 g/week in the 
first half of pregnancy and thereafter 400 g/week with 
a total weight gain of 10–15 kg. BMI 25–29.9 kg/m2: 
aiming for 100 g/week in the first half of pregnancy and 
thereafter 300 g/week, with a total weight gain of 5–8 kg. 
BMI≥30 kg/m2: aiming for 0 g/week in the first half of 
pregnancy and thereafter 200 g/week, with a total weight 
gain of 0–5 kg.
Self- monitored plasma glucose measurements were 
recommended seven times daily, aiming for preprandial 
plasma glucose values between 4 and 6 mmol/L and 90 
min postprandial values between 4 and 8 mmol/L. The 
aim for HbA1c was <6.7% (50 mmol/mol) in the first half 
of pregnancy and <5.8% (40 mmol/mol) in the second 
half of pregnancy.
Before pregnancy most women were treated with diet 
alone or in a combination with oral antidiabetic drugs 
and/or glucagon- like peptide-1 (GLP-1) analogs. At 
first pregnancy visit, the treatment with oral antidiabetic 
drugs and/or GLP-1 analogs was discontinued and not 
used during pregnancy. Therefore, insulin treatment was 
often initiated or tailored.
At each pregnancy visit, HbA1c and weight were 
measured, and a dipstick of sterile urine was screened for 
proteinuria and ketonuria. The daily insulin dose, the 
occurrence of mild hypoglycemia in the previous week 
and the median of each time point in the 7- point plasma 
glucose profile for 5 days were noted. These data were 
used for reinforcement of dietary advice and insulin dose 
adjustments.
 Procedure and data collection
For both cohorts, maternal clinical data were collected at 
first pregnancy visit (early pregnancy visit) and at 35–37 
weeks (late pregnancy visit). The women’s self- reported 
weight and height before pregnancy, age at inclusion, 
duration of diabetes, gestational age at first visit, parity, 
ethnicity and smoking were noted.
The women were weighted on calibrated electronic 
scales without shoes or heavy clothes to the nearest 0.1 
kg. Gestational weight gain was defined as the difference 
between measured weights at the early and the late preg-
nancy visits. Within the three BMI classes (normal weight 
(BMI<25 kg/m2), overweight (BMI 25–29.9 kg/m2) and 
obese (BMI≥30 kg/m2)) gestational weight gain was cate-
gorized as follows based on the Institute of Medicine 
(IOM) 2009 recommendation23: insufficient (<11.5, <7.0 
and<5.0 kg for the BMI classes, respectively), appropriate 
(11.5–16.0, 7.0–11.5 and 5.0–9.0 kg) and excessive (>16, 
>11.5 and >9 kg).
HbA1c was analyzed immediately by a DCA 2000 
analyzer by a latex immunoagglutination inhibition 
method (DCA 200; Bayer, Mishawaka, IN). Delta- HbA1c 
was defined as the difference between the HbA1c measure-
ments at the early and the late pregnancy visits. The urine 
was analyzed by Siemens CLINITEK Status+Analyzer. The 
occurrence of ketonuria was noted if the concentration 
of ketone bodies was ≥4.0 mmol/L. Diabetic retinopathy 
was assessed by retinal photoscreening and evaluated by 
an ophthalmologist. Diabetic nephropathy was defined 
as albumin- creatinine ratio ≥300 mg/g at the early preg-
nancy visit, based on two urine samples.
The data on maternal neck and ankle circumference 
and subcutaneous skinfolds were collected for the inter-
vention cohort at the early and the late pregnancy visits. 
Neck circumference was obtained in a standing relaxed 
position in the midway of the neck, between mid- cervical 
spine and mid- anterior neck to within 1 mm. Ankle 
circumference was measured 5 cm above the lateral malle-
olus at both ankles as a pragmatic estimate for the devel-
opment of peripheral edema. Skinfold thickness at four 
areas (biceps, triceps, suprailiac and subscapular) was 
measured to the nearest millimeters with a Harpenden 
caliper24 and given as a sum of skinfolds.
Furthermore, the women answered two questions in 
a questionnaire: ‘How motivated are you for achieving 
good glycemic control during pregnancy’ and ‘How 
motivated are you for achieving appropriate gestational 
weight gain during pregnancy’ on a Likert scale from 1 
to 10. A score ≥8 on the Likert scale was considered as 
very motivated. The coaches were motivated for using the 
motivational interviewing but were not asked about their 
own motivation.
The following data on pregnancy outcome were 
retrieved from the medical records: gestational age at 
delivery, preterm delivery (before 37 completed weeks), 
cesarean section (elective and emergency), shoulder 
dystocia and the sex of the infant. Weight, length, and 
abdominal and head circumference of the infant were 
measured shortly after birth. Birth weight z- score was 
calculated by local growth curves adjusted for gestational 
age and infant sex.25 LGA and small for gestational age 
(SGA) were defined as birth weight >90th and <10th 
percentiles, respectively. As only half of the population 
was of Northern European origin, the prevalence of LGA 
and SGA infants was calculated by two different methods: 
first, by traditional Nordic growth curves25 adjusted for 
gestational age and infant sex; second, by using custom-
ized birth weight centiles (gestation- related optional 
weight, GROW26) adjusted for maternal height, weight, 
ethnic origin, parity, gestational age and infant sex. Peri-
natal mortality (offspring death after 20 gestational weeks 
or within the first 7 days of life), major congenital malfor-
mations (leading to death, causing a substantial future 
handicap or requiring surgery), neonatal hypoglycemia 
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Figure 1 (A) Flowchart for inclusion in the intervention cohort. (B) Flowchart for inclusion in the reference cohort.
(defined as a plasma glucose value below 2.2 mmol/L, 
measured within 4 hours of life27), jaundice (requiring 
phototherapy), and transient tachypnea (requiring 
continuous positive airway pressure for more than 60 
min) were noted. Perinatal morbidity was defined as the 
occurrence of at least one of the following complications: 
major congenital malformation, neonatal hypoglycemia, 
jaundice or transient tachypnea.
In addition, the infants in the intervention cohort had 
skinfold measurements of triceps, quadriceps, suprailiac 
and subscapular region measured to the nearest milli-
meter and performed with a Harpenden skinfold 
caliper24 within 48 hours after birth.
 statistical analyses
Continuous data with normal distribution are reported 
as mean±SD, continuous data with skewed distribution 
as median (IQR) and categorical data as number (%). 
Comparison between the cohorts was performed by 
Student’s t- test, Mann- Whitney U test, χ2 test or Fisher’s 
exact test where appropriate. To control for the following 
covariates from the early pregnancy visit: nulliparity, 
smoking, pre- pregnancy BMI and HbA1c (%), an anal-
ysis of covariance was used for comparison of gestational 
weight gain and birth weight z- score between the cohorts. 
Statistical analyses were performed with IBM SPSS Statis-
tics V.22. Statistically significant differences were defined 
as a two- sided p<0.05.
A priori, we performed a simple power analysis. Based 
on our previous study,5 we assumed a prevalence of LGA 
of 20% and 35% in the two cohorts and with a power of 
80%, 135 women were needed in each cohort to detect a 
significant difference.
 ResulTs
In total, 116 and 103 women were included in the inter-
vention and the reference cohort, respectively. Thirteen 
women in the intervention cohort had a miscarriage and 
six women withdrew their consent, while in the reference 
cohort 10 women had a miscarriage and one woman 
moved from the uptake area, resulting in 97 (84%) and 
92 (89%) women being included in the final analyses 
(figure 1A, B).
At the early pregnancy visit, the intervention cohort 
and the reference cohort were comparable regarding 
pre- pregnancy BMI, duration of diabetes, HbA1c and 
fraction on insulin treatment (tables 1 and 2).
The intervention cohort was very motivated to achieve 
good glycemic control and appropriate gestational 
weight gain where 85% and 84% scored ≥8 on a Likert 
scale at the early pregnancy visit and 77% and 72% at the 
late pregnancy visit, respectively.
The total gestational weight gain was 9.2±5.8 kg in 
the intervention cohort vs 10.2±5.8 kg in the reference 
cohort, p=0.25, corresponding to a weekly gestational 
weight gain of 0.26±0.16 kg vs 0.28±0.16 kg, p=0.31, 
respectively (table 2). The percentage of women with 
excessive gestational weight gain was 34.4% (32/93) in 
the intervention cohort and 45.4% (40/88) in the refer-
ence cohort (p=0.13) (table 2), corresponding to 24% 
fewer cases with excessive gestational weight gain in the 
intervention cohort compared with the reference cohort. 
After adjustment for nulliparity, smoking, pre- pregnancy 
BMI and HbA1c (%) from the early pregnancy visit, the 
difference in gestational weight gain between the cohorts 
remained insignificant (p=0.24). Few women lost weight 
during pregnancy in the two cohorts (table 2).
Within the intervention cohort the sum of maternal 
skinfold measurements and neck circumference was 
unchanged during pregnancy, while the ankle circum-
ferences increased by 1.6 cm at each ankle, p<0.001 
(table 2).
During pregnancy, most women in both cohorts were 
treated with insulin, and at the late pregnancy visit the 
median daily insulin dose per kilogram body weight 
was 0.95 (0.66–1.51) IU/kg in the intervention cohort 
compared with 0.74 (0.40–1.28) IU/kg in the reference 
cohort (p=0.03) (table 2).
HbA1c was comparable at the early pregnancy 
(6.7%±1.1% vs 6.5%±1.3% (50±12 mmol/mol vs 48±14 
mmol/mol), p=0.32) and the late pregnancy (5.9%±0.5% 
vs 6.0%±0.6% (41±6 mmol/mol vs 42±7 mmol/mol), 
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Table 1 Clinical characteristics among pregnant women 
with type 2 diabetes in the intervention cohort compared 
with the reference cohort at the early pregnancy visit
Intervention 
cohort
Reference 
cohort P value
n 97 92
Age (years) 34±5 34±6 0.52
Duration of 
diabetes (years)
3 (1–8) 2.5 (0.5–5) 0.08
Diabetes 
retinopathy*
10 (12) 3 (5) 0.16
Diabetes 
nephropathy
1 (1) 0 1.00
North European 
origin
56 (58) 44 (48) 0.17
Nullipara 41 (42) 29 (32) 0.13
Smoker 10 (11) 18 (20) 0.13
Height (cm) 165.6±7.2 163.9±7.6 0.11
Pre- pregnancy 
BMI (kg/m2)
32.8±6.9 32.4±7.4 0.70
BMI classes
  ≤24.9 kg/m2 14 (14) 17 (18) 0.75
  25.0–29.9 kg/m2 21 (22) 19 (21)
  ≥30.0 kg/m2 62 (64) 56 (61)
Data are given as mean±SD, median (IQR) or n (%). Data available 
in 85%–100% unless otherwise stated.
*Data available from 87% vs 64%.
BMI, body mass index.
p=0.34) visits. However, the decline in HbA1c during preg-
nancy was greater in the intervention cohort compared 
with the reference cohort (−0.6 (−1.3 to −0.2)% vs −0.2 
(−1.0 to 0.1)% (−7 (−14 to −2) mmol/mol vs −2 (−11 to 
1) mmol/mol), p=0.01) (table 2).
The prevalence of LGA infants was 20% vs 31%, 
p=0.07, in the intervention cohort compared with the 
reference cohort (table 3). The figures when using the 
customized GROW curves, taking maternal character-
istics into account, were 14% vs 27%, p=0.04 (table 3). 
The intervention cohort delivered infants with a birth 
weight z- score of 0.24±1.36 compared with 0.61±1.38 
in the reference cohort (p=0.06). After adjustment for 
nulliparity, smoking, pre- pregnancy BMI and HbA1c 
(%) from the early pregnancy visit the difference in 
birth weight z- score remained insignificant between the 
cohorts (p=0.11). The occurrence of perinatal mortality 
and morbidity was similar in the two cohorts (table 3).
When restricting the analyses to the 86% of the inter-
vention cohort judged compliant to the intervention, 
similar gestational weight gain, occurrence of LGA 
infants and birth weight z- score were obtained as for the 
total cohort (data not shown).
Transient tachypnea of the newborn tended to be less 
common in the intervention cohort compared with the 
reference cohort (10% vs 20%, p=0.06), while major 
congenital malformation (p=0.68), neonatal hypogly-
cemia (p=0.86) and jaundice (p=0.38) were comparable 
between the cohorts (table 3).
When dividing the cohorts into women of North Euro-
pean origin and non- North European origin, comparable 
gestational weight gain was obtained in the intervention 
cohort (9.2±6.0 kg vs 9.2±5.5 kg, p=0.96) and in the 
reference cohort (9.7±6.2 vs 10.7±5.4, p=0.42). The prev-
alence of LGA infants was 20% vs 20%, p=0.99, in the 
intervention cohort and 37% vs 26%, p=0.23, in the refer-
ence cohort, respectively, with the birth weight z- score of 
0.11±1.25 vs 0.40±1.50, p=0.32, and 0.71±1.31 vs 0.52 vs 
1.44, p=0.53.
COnClusIOns
In this cohort study consisting of an intervention cohort 
and a historical reference cohort there was a trend 
towards a reduced prevalence of fetal overgrowth, when 
using motivational interviewing to improve adherence to 
healthy eating in addition to routine care. The average 
gestational weight gain was comparable between the 
cohorts.
To our knowledge, this is the first lifestyle intervention 
study performed in pregnant women with type 2 diabetes.
Although the women in the intervention cohort 
received additional help to improve motivation for 
healthier eating habits, it was still challenging for many 
of the women to achieve appropriate gestational weight 
gain. However, we found a non- significant reduction in 
excessive gestational weight gain of 24%, which is compa-
rable to the 23% reduction seen in healthy pregnant 
women exposed to dietary intervention16 and lower than 
the 41%–63% previously reported in the literature.5 13–15
Three randomized controlled trials (RCT) using life-
style intervention in healthy, overweight and obese 
pregnant women without diabetes found a reduced 
gestational weight gain of 1.5–2.3 kg in the intervention 
groups compared with the control groups20 28 29 while 
three studies showed no effect on the gestational weight 
gain.30–32 The obtained non- significant reduction in 
gestational weight gain of 1.0 kg in our study is thus close 
to what is obtained in healthy, overweight and obese 
women exposed to a lifestyle intervention.
The mean gestational weight gain in the intervention 
cohort was 9.2 kg, which is the same as the expected 
weight gain due to physiological changes in pregnancy, 
which has been estimated to 9.2 kg without taking the 
increase in maternal fat stores into account.33 The women 
in the intervention cohort had documented a stable sum 
of skinfolds throughout pregnancy but developed signs 
of peripheral edema in late pregnancy, indicating that 
edema formation without increase in maternal subcuta-
neous fat mass can explain some of the obtained weight 
gain.
Most of the published lifestyle studies chose a combi-
nation of diet and physical activity changes as the inter-
vention,16 including the DALI study.20 In the DALI study, 
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Table 2 Maternal glycemic control and weight changes during pregnancy among women with type 2 diabetes in the 
intervention cohort compared with the reference cohort
Intervention cohort Reference cohort P value
Gestational age at the early pregnancy visit (days) 83±26 76±23 0.04
HbA1c at the early pregnancy visit (%) 6.7±1.1 6.5±1.3 0.32
HbA1c at the early pregnancy visit (mmol/mol) 50±12 48±14
HbA1c at the late pregnancy visit (%) 5.9±0.5 6.0±0.6 0.34
HbA1c at the late pregnancy visit (mmol/mol) 41±6 42±7
∆HbA1c (%)* −0.6 (−1.3 to −0.2) −0.2 (−1.0 to 0.1) 0.01
∆HbA1c (mmol/mol) −7 (−14 to −2) −2 (−11 to 1)
Women with ketonuria at the early pregnancy visit (4–15.9 mmol/L) 2 (2) 5 (6) 0.25
Women with ketonuria at the late pregnancy visit (4–15.9 mmol/L) 2 (2) 3 (4) 0.67
Weight at the early pregnancy visit (kg) 91.9±22.0 89.6±23.5 0.48
Weight at the late pregnancy visit (kg) 101.3±21.3 100.3±23.8 0.78
Total gestational weight gain (kg) 9.2±5.8 10.2±5.8 0.25
Total gestational weight gain/week (kg) 0.26±0.16 0.28±0.16 0.31
Gestational weight gain according to IOM’s recommendations
Insufficient 29 (31.2) 24 (27.3) 0.31
Appropriate 32 (34.4) 24 (27.3)
Excessive 32 (34.4) 40 (45.4)
Women with weight loss during pregnancy 5 (5) 4 (5) 1.00
Neck circumference (cm)
  At the early pregnancy visit 37.5±4 – 0.24
  At the late pregnancy visit 37.7±4 –
Ankle circumference (cm)
  At the early pregnancy visit 24.1±3 – <0.001
  At the late pregnancy visit 25.7±4 –
Sum of skinfolds (cm)†
  At the early pregnancy visit (cm) 11.2±3.1 – 0.29
  At the late pregnancy visit 11.5±3.0 –
Women on insulin treatment before the early pregnancy visit 21 (23) 24 (28) 0.43
Women on insulin treatment at the late pregnancy visit 89 (96) 77 (89) 0.07
Insulin dose at the late pregnancy visit (IU/kg) 0.95 (0.66–1.51) 0.74 (0.40–1.28) 0.03
Women with ≥1 episode of hypoglycemia the previous week at the late 
pregnancy visit‡
39 (47) 16 (28) 0.02
Data are given as mean±SD, median (IQR) or n (%). Data available in 87%–100% unless otherwise stated.
*∆HbA1c was defined as the difference between measurements at the early and the late pregnancy visits.
†Sum of skinfold measurements of triceps, quadriceps, subscapular and suprailiac region.
‡Insulin- treated women only, with data available from 93% vs 74%, respectively.
IOM, Institute of Medicine.
a 2.3 kg lower gestational weight gain and reduced 
offspring adiposity measured by the sum of skinfolds was 
documented in the intervention group compared with 
the control group.20 34 However, the compliance to the 
exercise part of the intervention has been documented 
low28 35 36 and a reduction in physical activity during preg-
nancy is reported.35 36 Aiming for a successful compliance 
to lifestyle changes, it is probably important to limit the 
number of tasks to change, and we asked the women to 
focus only on one of the dietary goals at a time. Whether 
the effect on gestational weight gain and fetal growth 
might have been more pronounced if goals for physical 
activity were added to the dietary intervention needs 
further investigation.
The intervention was not associated with a lower need 
for insulin; contrary, the intervention cohort received a 
higher insulin dose and had more often hypoglycemia 
at the late pregnancy visit compared with the reference 
cohort. Insulin is a growth factor and both insulin and 
hypoglycemia stimulate appetite and this may have influ-
enced the effect on the gestational weight gain.
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Table 3 Pregnancy outcomes among women with type 2 diabetes in the intervention cohort compared with the reference 
cohort
Intervention cohort
(n=97)
Reference cohort
(n=92) P value
Gestational age at delivery (days) 263 (260–270) 266 (259–268) 0.98
Preterm delivery (<37 weeks) 19 (20) 16 (17) 0.70
Cesarean section 44 (45) 46 (51) 0.48
Shoulder dystocia 1 (1) 1 (1) 1.00
Female offspring 41 (42) 48 (52) 0.17
Birth weight (g) 3167±659 3324±636 0.10
Birth length (cm) 50.4±3 50.5±2 0.85
Abdominal circumference (cm) 32.2±2 32.8±2 0.15
Head circumference (cm) 34.4±2 34.4±2 0.90
Sum of skinfolds (cm)* 2.21 (1.88–2.75) –
Birth weight z- score 0.24±1.36 0.61±1.38 0.06
Large for gestational age (Nordic curves)† 19 (20) 28 (31) 0.07
Small for gestational age (Nordic curves)† 11 (11) 5 (6) 0.16
Large for gestational age (GROW curves)‡ 14 (14) 24 (27) 0.04
Small for gestational age (GROW curves)‡ 14 (14) 7 (8) 0.15
Perinatal mortality 1 (1) 1 (1) 1.00
Perinatal morbidity§ 34 (35) 37 (42) 0.39
  Major congenital malformations 2 (2) 3 (3) 0.68
  Neonatal hypoglycemia (<2.2 mmol/L) 15 (16) 14 (17) 0.86
  Jaundice 15 (16) 10 (11) 0.38
  Transient tachypnea 10 (10) 18 (20) 0.06
Data are given as median (IQR), n (%) or mean±SD. Only live births included and one woman in the reference cohort gave birth at another 
hospital and detailed data are missing. Data available from 87% to 100% if not otherwise stated.
*Sum of skinfold measurements of triceps, quadriceps, subscapular and suprailiac region, data on 58%.
†>90th and <10th percentiles using Nordic growth curves adjusted for gestational age and infant sex.
‡>90th and <10th percentiles using customized birth weight centiles adjusted for maternal height, weight, ethnic origin and parity in addition 
to gestational age and infant sex (gestation- related optional weight, GROW).
§Perinatal morbidity was defined as the occurrence of at least one of the following complications: major congenital malformation, neonatal 
hypoglycemia, jaundice and transient tachypnea.
The birth weight z- score is based on growth curves for 
a Nordic population.25 Half of the women in this study 
were of other ethnic origin and therefore data on infant 
overgrowth are given both using the Nordic growth 
curves adjusted for gestational age and infant sex and the 
customized growth curves by GROW26 where maternal 
height, weight, ethnic origin, parity, and gestational age 
and infant sex are taken into account, too. It is reassuring 
that the prevalence of LGA infants is similar regardless 
of the method used. The observed reduction in average 
birth weight z- score and the prevalence of LGA infants 
in this study is clinically meaningful. It did not convert 
to significantly reduced perinatal morbidity, but whether 
this reduction in fetal overgrowth will affect the long- 
term risk of obesity and type 2 diabetes later in life 
remains speculative. The occurrence of SGA infants in 
this study is close to the 10% expected in the background 
population.
Whether the more appropriate fetal growth in the 
intervention cohort could be explained mainly by moti-
vational interviewing leading to healthier eating habits 
or whether the more intensive insulin therapy in the 
intervention cohort played the major role cannot be 
determined from our results. However, it is known that 
maternal lipids and protein consumption as well as 
micronutrients affect fetal growth.37 It is possible that 
the women in the intervention cohort established overall 
better eating habits compared with the reference cohort, 
resulting in more appropriate fetal growth, not mediated 
by restricted gestational weight gain. Possible differences 
in nulliparity, smoking, pre- pregnancy BMI, and glycemic 
control between the groups at the early pregnancy visit 
have been taken into account by performing statistical 
analyses with and without these covariates.
The clinical benefits of avoiding transient tachypnea 
include better possibilities for skin- to- skin contact, mater-
nal–child bonding and successful breast feeding. Both 
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fetal overgrowth and transient tachypnea of the newborn 
tended to be less common in the intervention cohort. 
Whether this is related to less fetal hyperinsulinemia 
needs to be clarified in further studies.
It is a strength that this cohort study included consecu-
tive women with type 2 diabetes from a large population 
with very few exclusion criteria and was conducted in a 
real- world setting. Therefore, we are most likely studying 
an unselected population of pregnant women with type 
2 diabetes, also including the vulnerable women from 
more deprived areas. This makes the study results appli-
cable to the relevant population. In an RCT, vulnerable 
women would often not participate even though they 
probably were the ones needing motivation for lifestyle 
changes the most. Another potential problem with an 
RCT including lifestyle interventions is the Hawthorne 
effect, that is, the women accepting inclusion are often 
very motivated, which results in improved lifestyle in 
the control group, too. This is not the case in our study 
where a historical cohort that was totally unaware of 
the intervention was included. The study was planned 
with a minimal excess use of one- to- one contact with a 
caregiver and the women followed their routine visits, 
enabling the women to participate regardless of parity, 
economy or occupation. Furthermore, this enables the 
motivational interviewing technique to be implemented 
as routine care. However, resources of an extra diabetes 
caregiver of approximately 240 min per women were 
applied.
By including measurements of maternal skinfolds and 
ankle circumferences, we obtained a rough estimate of 
changes in maternal subcutaneous fat and fluid retention.
The limitation of ending up with insufficient numbers 
of women in this study was sought minimized by including 
women at two centers over a 2.5- year inclusion period. 
However, a large proportion of our pregnant women with 
type 2 diabetes had insufficient Danish skills and could 
for ethical reasons not be included.
A participation in a clinical trial often enhances 
general awareness of the participant and the caregiver 
and it is possible that there has been more focus on 
appropriate insulin treatment in the intervention cohort. 
On the other hand, healthy eating may reduce hypergly-
cemia and enable the women to obtain more sufficient 
insulin treatment without suffering from pronounced 
hypoglycemia.
An evaluation of the maternal food intake including 
carbohydrate, fat and protein intake as well as physical 
activity would have improved the study.
The lifestyle coaches were two midwives with special 
education and training in the motivational interviewing 
with focus on healthy eating and had years of experience 
from the DALI study where using midwifes was docu-
mented effective.20 The women in both cohorts received 
dietary guidance by a registered dietitian according to 
local practice. Whether training of the local dietitian in 
the motivational interviewing would have given different 
results remains speculative.
The goals for the gestational weight gain for the 
women in both cohorts were according to the Copen-
hagen guidelines that are stricter than the IOM guide-
lines. However, the weight gain was given as insufficient/
appropriate/excessive according to the IOM guidelines 
in order to compare the results with other studies.
In conclusion, motivational interviewing to improve 
adherence to healthy eating in addition to routine care 
in women with type 2 diabetes tended to reduce fetal 
overgrowth without major effect on gestational weight 
gain. Further studies investigating the cost- benefit of 
enhancing motivation for adherence to treatment goals 
are needed.
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